Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830096 | 0.98 | P2RX7 (0.38) | P2RX7MEN1KMT2AEPHX2OPRK1 | |
| SCHEMBL1734016 | 0.87 | P2RX7 (0.35) | P2RX7MEN1KMT2AEPHX2OPRK1 | |
| SCHEMBL3000346 | 0.86 | P2RX7 (0.34) | P2RX7MEN1KMT2AEPHX2CYP11B1 | |
| SCHEMBL1735054 | 0.86 | P2RX7 (0.32) | P2RX7MEN1KMT2AEPHX2OPRK1 | |
| SCHEMBL2170720 | 0.86 | P2RX7 (0.32) | P2RX7MEN1KMT2AEPHX2OPRK1 | |
| SCHEMBL727665 | 0.85 | CYP2D6 (0.44) | MEN1KMT2AEPHX2ALDH1A1HPGD | |
| SCHEMBL16524441 | 0.84 | RAB9A (0.34) | P2RX7MEN1KMT2AEPHX2OPRK1 | |
| SCHEMBL1423104 | 0.83 | P2RX7 (0.34) | P2RX7MEN1KMT2AEPHX2OPRK1 | |
| SCHEMBL289717 | 0.82 | OPRK1 (0.42) | P2RX7MEN1KMT2AEPHX2OPRK1 | |
| SCHEMBL3685420 | 0.82 | P2RX7 (0.32) | P2RX7MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082157-A | Method for preparing organic carboxylic ester by olefine unsaturated compound alkoxycarbonyl reaction | 上海梓龄化工技术有限公司 | 2023-05-09 | — | — | CN | claimed |
| EP-2794548-B1 | A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INT UK LTD (GB) | 2019-05-15 | — | — | EP | claimed |
| US-9382190-B2 | Continuous process for the carbonylation of ethylene | LUCITE INTERNATIONAL UK LIMITED (GB) | 2016-07-05 | — | — | US | claimed |
| US-20150099896-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INTERNATIONAL UK LIMITED (GB) | 2015-04-09 | — | — | US | claimed |
| EP-2794548-A1 | A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | Lucite International UK Limited (GB) | 2014-10-29 | — | — | EP | claimed |
| EP-1931471-B1 | CONTINUOUS CARBONYLATION PROCESS | LUCITE INT UK LTD (GB) | 2014-10-01 | — | — | EP | claimed |
| EP-2007703-B1 | METAL COMPLEXES FOR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INT UK LTD (GB) | 2013-12-18 | — | — | EP | claimed |
| US-8604236-B2 | Catalyst system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2013-12-10 | — | — | US | claimed |
| WO-2013093472-A1 | A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INTERNATIONAL UK LIMITED (GB) | 2013-06-27 | — | — | WO | claimed |
| US-8445711-B2 | Metal complexes | LUCITE INTERNATIONAL UK LIMITED (GB) | 2013-05-21 | — | — | US | claimed |
| WO-2007119079-A1 | METAL COMPLEXES FOR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2007-10-25 | — | — | WO | claimed |
| US-7265240-B2 | With CO in the presence of a source of hydroxyl groups (water or an alcohol) and a catalyst obtained by combining a Group VIII metal or a compound thereof and a bidentate phosphine, e.g., tri(dibenzylideneacetone)di-palladium | LUCITE INTERNATIONAL UK LIMITED (GB) | 2007-09-04 | — | — | US | claimed |
| WO-2007020379-A1 | IMPROVED CATALYST SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2007-02-22 | — | — | WO | claimed |
| US-20060128985-A1 | Carbonylation of vinyl acetate | LUCITE INTERNATIONAL, INC. | 2006-06-15 | — | — | US | claimed |
| US-20060122435-A1 | Process for the carbonylation of ethylenically unsaturated compounds | LUCITE INTERNATIONAL UK LIMITED (GB) | 2006-06-08 | — | — | US | claimed |
| EP-1651587-A1 | PROCESS FOR THE HYDROFORMYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | Lucite International UK Limited (GB) | 2006-05-03 | — | — | EP | claimed |
| JP-2006508162-A | — | — | 2006-03-09 | — | — | JP | claimed |
| EP-1565425-A1 | CARBONYLATION OF VINYL ACETATE | Lucite International UK Limited (GB) | 2005-08-24 | — | — | EP | claimed |
| WO-2005003070-A1 | PROCESS FOR THE HYDROFORMYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2005-01-13 | — | — | WO | claimed |
| WO-2004050599-A1 | CARBONYLATION OF VINYL ACETATE | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-06-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128985-A1 | Carbonylation of vinyl acetate | PCCA, LDHA, PC | P2RX7 3916/4885MEN1 3713/4885KMT2A 1956/4885 |
| US-20150099896-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | SCD, ELOVL6, ALK | P2RX7 4835/4885MEN1 3844/4885KMT2A 3010/4885 |
| US-20060122435-A1 | Process for the carbonylation of ethylenically unsaturated compounds | CYC1, CYCS, COX5A | P2RX7 2637/4885MEN1 3492/4885KMT2A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.